Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.20.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents [note 5] $ 12,156 $ 16,664
Amounts receivable   8
Prepaid expenses and other assets 746 662
Total current assets 12,902 17,334
Restricted cash [note 5] 50 50
Property and equipment, net 52 57
Right-of-use assets [note 7] 285 329
Other assets 293 187
License agreement [note 3 and 4] 2,031 2,087
Goodwill [note 4] 1,034 1,034
Total assets 16,647 21,078
Current liabilities:    
Accounts payable 184 859
Accrued liabilities other 174 304
Accrued clinical liabilities 571 387
Accrued compensation 419 1,116
Current portion of long-term obligations [note 7] 196 203
Total current liabilities 1,544 2,869
Long-term obligations [note 7] 118 159
Total liabilities 1,662 3,028
Commitments and contingencies [note 7]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 31,352,764 issued and outstanding at March 31, 2020 and 29,485,178 issued and outstanding at December 31, 2019, respectively. 43 41
Additional paid-in capital 63,962 63,709
Accumulated deficit (49,024) (45,704)
Accumulated other comprehensive income 4 4
Total stockholders' equity 14,985 18,050
Total liabilities and stockholders' equity 16,647 21,078
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value